Nefazodone-induced clitoral priapism.

abstract：:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

journal_title：International clinical psychopharmacology

authors： Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

更新日期：2001-11-01 00:00:00

abstract：:The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Rapaport M,Weizman A

更新日期：2017-09-01 00:00:00

abstract：:A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

journal_title：International clinical psychopharmacology

authors： Frith CD

更新日期：1995-09-01 00:00:00

abstract：:A total of 101 patients entered a double-blind, parallel-group study in general practice, comparing the efficacy and tolerability of paroxetine and amitriptyline in elderly depressed patients. All patients received placebo for 1 week followed by active therapy for a total of 6 weeks. Medication was randomly allocated,...

journal_title：International clinical psychopharmacology

authors： Hutchinson DR,Tong S,Moon CA,Vince M,Clarke A

更新日期：1992-06-01 00:00:00

abstract：:Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

journal_title：International clinical psychopharmacology

authors： Mattila M,Seppala T,Mattila MJ

更新日期：1988-07-01 00:00:00

abstract：:The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...

journal_title：International clinical psychopharmacology

authors： Hayashi T,Yokota N,Takahashi T,Tawara Y,Nishikawa T,Yano T,Furutani M,Fujikawa T,Horiguchi J,Yamawaki S

更新日期：1997-07-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...

journal_title：International clinical psychopharmacology

authors： Davidson JR,Malik ML,Sutherland SN

更新日期：1997-11-01 00:00:00

abstract：:Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. This selectivity has been demonstrated not only for monoamine uptake mechanisms but also for neurotransmitter receptor systems. The pharmacokinetic studies indicate that paroxetine may be administered...

journal_title：International clinical psychopharmacology

authors： Johnson AM

更新日期：1992-06-01 00:00:00

abstract：:Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

journal_title：International clinical psychopharmacology

authors： Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

更新日期：2006-11-01 00:00:00

abstract：:The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

journal_title：International clinical psychopharmacology

authors： Schutz G,Berk M

更新日期：2001-09-01 00:00:00

abstract：:Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

journal_title：International clinical psychopharmacology

authors： Emsley RA,Raniwalla J,Bailey PJ,Jones AM

更新日期：2000-05-01 00:00:00

abstract：:Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...

journal_title：International clinical psychopharmacology

authors： Liebowitz MR,Heimberg RG

更新日期：1996-06-01 00:00:00

abstract：:C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

journal_title：International clinical psychopharmacology

authors： Kim SH,Reaven G,Lindley S

更新日期：2011-01-01 00:00:00

abstract：:The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

journal_title：International clinical psychopharmacology

authors： Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

更新日期：2005-03-01 00:00:00

abstract：:Leukopenia and agranulocytosis are well reported and dangerous haematological side-effects associated with the use of typical and atypical antipsychotics. These potentially life-threatening phenomena have led to treatment discontinuation and the consequent reemergence of psychiatric symptoms. We report three cases of ...

journal_title：International clinical psychopharmacology

authors： Kodesh A,Finkel B,Lerner AG,Kretzmer G,Sigal M

更新日期：2001-03-01 00:00:00

abstract：:Serotonin is a key neurotransmitter in the central nervous system. In recent years its role in the pathophysiology and pharmacology of depression has been extensively investigated. Neuroendocrine studies suggest decreased serotonergic responsivity in patients with major depression. The fact that the majority of patien...

journal_title：International clinical psychopharmacology

authors： Dinan TG

更新日期：1996-03-01 00:00:00

abstract：:The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

journal_title：International clinical psychopharmacology

authors： Piwernetz K

更新日期：2001-04-01 00:00:00

abstract：:Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...

journal_title：International clinical psychopharmacology

authors： van Os J,Bossie CA,Lasser RA

更新日期：2004-07-01 00:00:00

abstract：:The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

journal_title：International clinical psychopharmacology

authors： Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

更新日期：1987-01-01 00:00:00

abstract：:Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...

journal_title：International clinical psychopharmacology

authors： Drago A,Kure Fischer E

更新日期：2018-01-01 00:00:00

abstract：:The effect of adjunctive fluoxetine on negative schizophrenic symptoms was evaluated in 34 chronic schizophrenic in-patients on maintenance therapy with neuroleptics. They received randomly, on a double-blind basis, fluoxetine (20 mg/day) or placebo for 12 weeks. In the fluoxetine group, three patients dropped out bec...

journal_title：International clinical psychopharmacology

authors： Spina E,De Domenico P,Ruello C,Longobardo N,Gitto C,Ancione M,Di Rosa AE,Caputi AP

更新日期：1994-01-01 00:00:00

abstract：:This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n= 30) or placebo (n= 30) for 12 weeks in a double-blind study design. Prima...

journal_title：International clinical psychopharmacology

authors： Schutters SI,Van Megen HJ,Van Veen JF,Denys DA,Westenberg HG

更新日期：2010-09-01 00:00:00

abstract：:The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

journal_title：International clinical psychopharmacology

authors： Landry P,Warnes H,Nielsen T,Montplaisir J

更新日期：1999-05-01 00:00:00

abstract：:Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

journal_title：International clinical psychopharmacology

authors： Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

更新日期：1996-06-01 00:00:00

abstract：:Panic disorder has recently been recognized as a distinct sub-type of anxiety which may occur with or without phobic avoidance. Controlled prospective trials have demonstrated the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of this disorder. The use of benzodiazepines an...

journal_title：International clinical psychopharmacology

authors： Judd FK,Norman TR,Burrows GD

更新日期：1986-01-01 00:00:00

abstract：:The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

journal_title：International clinical psychopharmacology

authors： Barak Y,Swartz M,Plopsky I

更新日期：2005-11-01 00:00:00

abstract：:We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...

journal_title：International clinical psychopharmacology

authors： Ashoorian DM,Davidson RM,Rock DJ,Dragovic M,Clifford RM

更新日期：2015-07-01 00:00:00

abstract：:In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...

journal_title：International clinical psychopharmacology

authors： Lindström E,Widerlöv B,von Knorring L

更新日期：1996-12-01 00:00:00

abstract：:Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment. At follow-up most patients (74%) did not suffer from panic attacks at all. In the beginnin...

journal_title：International clinical psychopharmacology

authors： Lepola UM,Rimón RH,Riekkinen PJ

更新日期：1993-07-01 00:00:00